Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

Subscriber?

NeoGenomics Spends $37M for Human Longevity’s Oncology Division

This acquisition shows NeoGenomics going strong into next-gen gene sequencing for cancer patients

Once again, Neogenomics, Inc. is using an  acquisition  to  build  up  its cancer-testing business. In a deal that closed on Jan. 10, the lab company acquired the Oncology Division of Human Longevity, based in San Diego. Neogenomics said it paid $37 million for the division of Human Longevity that does next-generation sequencing services for pharmaceutical …

NeoGenomics Spends $37M for Human Longevity’s Oncology Division Read More »

To access this post, you must purchase The Dark Report.

Comments

Volume XXVII No. 2 – January 27, 2020

TABLE OF CONTENTS

COMMENTARY & OPINION BY R. LEWIS DARK

ARTICLES

INTELLIGENCE

Need A Group Membership? Company Discounts are Available!

Get More Information Now!
Facebook-f Twitter Linkedin-in

The Dark Report • 21806 Briarcliff Dr • Spicewood, TX 78669
Phone: 512-264-7103 • Toll Free Number: 800-560-6363
Email: customerservice@darkintelligencegroup.com

© 2022 The Dark Report. All rights reserved.

;